In MSD we are passionate about advancing healthcare needs and providing life-saving medicines to patients through innovation. We cannot do this without the expert advice and insights of healthcare professionals (HCPs) and healthcare organisations (HCOs).
The healthcare profession offers invaluable expert knowledge about the management of disease. Our collaboration is critical to the future of medical research and our efforts to improve patient care and treatment options.
As would be expected, it is important that interactions with professionals in healthcare meet the highest standards of integrity that patients, governments and other stakeholders expect. Relations between the wider pharmaceutical sector including MSD, and HCPs are closely regulated.
The pharmaceutical industry is committed to greater transparency of financial relationships with the healthcare profession. As a member of the Irish Pharmaceutical Healthcare Association (IPHA), we have been actively engaged in ensuring full disclosure of any payments to HCPs and HCOs.
This public disclosure is a proactive initiative by the pharmaceutical industry and marks a significant development in the relationship between industry and HCPs.
From 30th June 2016, MSD along with other IPHA member companies, are disclosing details of 'Transfer of Value' payments and benefits to individually named HCPs and HCOs on a publicly searchable database on the Irish Pharmaceutical Healthcare Association website.
For details of MSD's individual payments to HCPs and HCOs, click here.
Before accessing the payment details you will be requested to review our methodology statement which outlines the scope of our disclosure including the consent management and collection process and also provides definitions of terminology used.